Benzinga | Jul 12, 2021 08:59AM EDT

Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate

* Aptorum Group Limited (NASDAQ:APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus.

* Specifically, two additional cohorts (Cohort C & D) of the single ascending dose portion of the Phase 1 trial in healthy subjects have been completed with no serious adverse events observed.

* No subjects were dropped out of the studies, and no serious adverse events were observed.

* Additionally, no clinically relevant changes regarding vital signs, electrocardiogram, clinical laboratory test results and physical examinations were observed compared to baselines.

* The single ascending dose is still ongoing to gain additional insights into the effect of food on bioavailability and pharmacokinetics.

* On this basis, the company plans to proceed to the multiple ascending dose part in 3Q of 2021.

* In May, the company completed two initial cohorts of the single-dose ascending dose portion of the Phase 1 trial.

* Price Action: APM shares are up 4.64% at $3.16 during the premarket session on the last check Monday.